Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

NCT04775745 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

CLL/SLL
Waldenstrom Macroglobulinemia
Follicular Lymphoma
Diffuse Large B Cell Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Hairy Cell Leukemia

Interventions

DRUG: LP-168
DRUG: LP-168

Sponsor

Newave Pharmaceutical Inc